Raymond James downgrades Boston Scientific stock rating on growth concerns

robot
Abstract generation in progress

Raymond James has downgraded Boston Scientific (NYSE:BSX) from Strong Buy to Outperform and reduced its price target to $88.00 from $97.00, citing concerns about slower growth in key areas like U.S. electrophysiology and Watchman. Despite the downgrade, the firm still considers Boston Scientific a high-quality, fast-growing company in medical technology. The stock is currently trading near its 52-week low, and while growth concerns are noted, the firm believes the current stock price largely reflects these issues.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin